High frequency of BRAF mutations in nevi
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
To evaluate the timing of mutations in BRAF (v-raf murine sarcoma viral oncogene homolog B1) during melanocytic neoplasia, we carried out mutation analysis on microdissected melanoma and nevi samples. We observed mutations resulting in the V599E amino-acid substitution in 41 of 60 (68%) melanoma metastases, 4 of 5 (80%) primary melanomas and, unexpectedly, in 63 of 77 (82%) nevi. These data suggest that mutational activation of the RAS/RAF/MAPK pathway in nevi is a critical step in the initiation of melanocytic neoplasia but alone is insufficient for melanoma tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, the BRAF oncogenic mutation found in more than half of all malignant cutaneous melanomas is commonly found also in non-malignant nevi, where it causes oncogene-induced senescence exemplified by high levels of CDKN2A and SA-β-gal expression225–227.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [226]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Busca, R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.12.2900 · Cited by 326
The Regulation of Normal Melanocyte Proliferation
Halaban, R. (2000) · Pigment Cell Research · doi:10.1034/j.1600-0749.2000.130103.x · Cited by 179
Research works printed but not linked: 2
- Armstrong, B.K. & English, D.R. in Cancer Epidemiology and Prevention (Oxford University Press, New York, 1996).
- Elder, D.E. & Murphy, G.F. in Atlas of Tumor Pathology: Melanocytic Tumors of the Skin 5–101 (Armed Forces Insititute of Pathology, Washington, DC, 1991).
Cited by
Items 801–900 of 1,001
Kudchadkar, R. R., Smalley, K. S. M., Glass, L. F., Trimble, J. S., & Sondak, V. K. (2013) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2012.08.013 · Cited by 38
Léon-Letelier, R. A., Bonifaz, L. C., & Fuentes‐Pananá, E. M. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0618-241rr · Cited by 31
Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy
Ishitsuka, Y., Hanaoka, Y., Tanemura, A., & Fujimoto, M. (2021) · Cancers · doi:10.3390/cancers13051148 · Cited by 29
“Specifically, MNs harbor BRAFV600E mutations with a similar frequency as melanomas [146], suggesting that the accumulation of activating mutation is the early neoplastic event of MN development [147].”
BackgroundB-Raf specific antibody responses in melanoma patients
Fensterle, J., Becker, J. C., Potapenko, T., Veronika, H., Vetter, C. S., Bröcker, E., & Rapp, U. R. (2004) · BMC Cancer · doi:10.1186/1471-2407-4-62 · Cited by 29
“The first conclusion is supported by studies demonstrating that the mutations already occur in melanocytic nevi at frequencies comparable to late stage melanoma [8], are not correlated with clinical outcome [25] and finally the Raf inhibitor Bay 43-9006 seems to have only moderate efficiency in advanced melanoma as re…”
Antiproliferative Effect of Rottlerin on Sk-Mel-28 Melanoma Cells
Daveri, E., Valacchi, G., Romagnoli, R., Maellaro, E., & Maioli, E. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/545838 · Cited by 29
“However, B-RAF mutations alone are not sufficient to explain melanomagenesis since also benign nevi frequently have B-RAF mutations [4, 5].”
BackgroundRetractedHacker, E., Irwin, N., Muller, H. K., Powell, M. B., Kay, G. F., Hayward, N. K., & Walker, G. J. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23917.x · Cited by 29
“There is a high frequency of BRAF and NRAS mutation in melanocytic nevi and MM (e.g. Davies et al., 2002; Pollock et al., 2003 and reviewed in de Snoo & Hayward, 2005; Rodolfo et al., 2004).”
Self-citationMourah, S., Denis, M. G., Escande, F., Solassol, J., Merlin, J., Sabourin, J., Scoazec, J., Ouafik, L., Emile, J., Heller, R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120232 · Cited by 32
Hornsby, P. J. (2009) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-009-0723-6 · Cited by 29
“Most nevi have a mutation of the BRAF oncogene and also have markers of cellular senescence [46, 57 ], although they do not have short telomeres [46].”
BackgroundMarchetti, M. A., Kiuru, M. H., BUSAM, K. J., Marghoob, A. A., Scope, A., Dusza, S. W., Cordova, M. A., Fonseca, M., Wu, X., & Halpern, A. C. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13260 · Cited by 29
Song, J., Mooi, W. J., Petronic-Rosic, V. M., Shea, C. R., Stricker, T. P., & Krausz, T. N. (2011) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3182169b69 · Cited by 29
“However, these mutations are also common in nevi.(52) Whether this finding is useful for the differential diagnosis of Spitz nevus versus melanoma is controversial.”
BackgroundFrequent oncogenic BRAF V600E mutation in odontogenic keratocyst
Cha, Y. H., Cho, E. S., Kang, H. E., Ko, J., Nam, W., Kim, H. J., Kim, N. H., Kim, H. S., Cha, I., & Yook, J. I. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.09.016 · Cited by 31
Stricker, T. P., & KUMAR, V. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0792-2.50012-2 · Cited by 60
Non-oxime inhibitors of B-RafV600E kinase
Ren, L. M., Wenglowsky, S., Miknis, G., Rast, B., Buckmelter, A. J., Ely, R. J., Schlachter, S. T., Laird, E. R., Randolph, N., Callejo, M., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.061 · Cited by 29
Modeling gene–environment interactions in malignant melanoma
Merlino, G. T., & Noonan, F. P. (2003) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(03)00006-6 · Cited by 32
The Keratinocyte in the Picture Cutaneous Melanoma Microenvironment
Marrapodi, R., & Bellei, B. (2024) · Cancers · doi:10.3390/cancers16050913 · Cited by 32
“Melanocytic nevi are precancerous lesions resulting from a focal and limited proliferation of melanocytes driven by the mutational activation of an oncogene such as BRAF [63].”
BackgroundStadelmeyer, E., Heitzer, E., Resel, M., Cerroni, L., Wolf, P., & Dandachi, N. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.338 · Cited by 28
Molecular testing in malignant melanoma
Grossmann, A. H., Grossmann, K. F., & Wallander, M. L. (2012) · Diagnostic Cytopathology · doi:10.1002/dc.22810 · Cited by 28
Ko, J., Vélez, N. F., & Tsao, H. (2010) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2010.10.004 · Cited by 34
The role of reactivity in DNA templated native chemical PNA ligation during PCR
Roloff, A., & Seitz, O. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.04.064 · Cited by 29
DeCarlo, K., Yang, S., Emley, A., Wajapeyee, N., Green, M., & Mahalingam, M. (2010) · Human Pathology · doi:10.1016/j.humpath.2009.12.002 · Cited by 28
“Several lines of evidence indicate that acquisition of a mutation in BRAF is a crucial step in melanocytic neoplasia [9-13].”
BackgroundInfluentialRoy, S. F., Milante, R. R., Pissaloux, D., Tirode, F., Bastian, B. C., de la Fouchardière, A., & Yeh, I. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100149 · Cited by 28
Cell Proliferation in Cutaneous Malignant Melanoma: Relationship with Neoplastic Progression
Pierard, G. (2012) · ISRN Dermatology · doi:10.5402/2012/828146 · Cited by 30
“The presence of BRAF mutations in melanocytic nevi suggests that a single BRAF mutation in the MAPK pathway as found in CMM is probably inadequate to promote malignant transformation [109, 119, 120, 123, 124].”
BackgroundGreen, J. S., Norris, D. A., & Wisell, J. A. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12279 · Cited by 28
Ostalecki, C., Lee, J.-H., Dindorf, J., Collenburg, L., Schierer, S., Simon, B., Schliep, S., Kremmer, E., Schuler, G., & Baur, A. S. (2017) · Science Signaling · doi:10.1126/scisignal.aai8288 · Cited by 31
Pawlikowski, J. S., Brock, C., Chen, S., Al-Olabi, L., Nixon, C., McGregor, F., Paine, S., Chanudet, E., Lambie, W., Holmes, W. M., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.114 · Cited by 32
“Specifically, their formation is thought to depend on activated NRAS or BRAF signaling, due to oncogenic mutation of NRAS or BRAF (Omholt et al., 2002; Pollock et al., 2003), and also depends on input from the Wnt signaling pathway (Pawlikowski et al.”
Novel inhibitors in the treatment of metastatic melanoma
Kalinsky, K. M., & Haluska, F. G. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.5.715 · Cited by 28
Qi, X., Bertling, K., Stark, M. S., Taimre, T., Kao, Y.-C., Lim, Y. L., Han, S., O’Brien, B., Collins, A., Walsh, M. D., et al. (2023) · Biomedical Optics Express · doi:10.1364/boe.480615 · Cited by 27
Self-citationActivating BRAF mutations in eruptive melanocytic naevi
Sekulic, A., Colgan, M. B., Davis, M. D. P., DiCaudo, D. J., & Pittelkow, M. R. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.09989.x · Cited by 27
McClenahan, P., Lin, L. L., Tan, J. M., Flewell‐Smith, R., Schaider, H., Jagirdar, K., Atkinson, V. G., Lambie, D., Prow, T. W., Sturm, R. A., et al. (2014) · JAMA Dermatology · doi:10.1001/jamadermatol.2014.436 · Cited by 27
McCormack, C. J., Conyers, R. K., Scolyer, R. A., Kirkwood, J. M., Speakman, D., Wong, N., Kelly, J. W., & Henderson, M. A. (2014) · Melanoma Research · doi:10.1097/cmr.0000000000000084 · Cited by 27
Mooradian, M. J., Reuben, A., Prieto, P. A., Hazar-Rethinam, M. H., Frederick, D. T., Nadres, B., Piris, A., Juneja, V. R., Cooper, Z. A., Sharpe, A. H., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1423172 · Cited by 27
“mon), resulting in constitutive activation of the MAPK pathway.(4,5) The resultant unopposed, constitutive activation of”
BackgroundMassively parallel sequencing analysis of benign melanocytic naevi
Lozada, J. R., Geyer, F. C., Selenica, P., Brown, D. N., Alemar, B., Merghoub, T., Berger, M. F., BUSAM, K. J., Halpern, A. C., Weigelt, B., et al. (2019) · Histopathology · doi:10.1111/his.13843 · Cited by 26
Cell free circulating tumor nucleic acids, a revolution in personalized cancer medicine
Kerachian, M. A., Poudineh, A., & Thiery, J. P. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102827 · Cited by 27
Richmond‐Sinclair, N. M., Lee, E., Cummings, M. C., Williamson, R., Müller, K., Green, A. C., Hayward, N. K., & Whiteman, D. C. (2008) · Melanoma Research · doi:10.1097/cmr.0b013e32830d8329 · Cited by 27
Self-citationInvestigative pathology: leading the post-genomic revolution
Berman, D. M., Bosenberg, M., Orwant, R., Thurberg, B. L., Draetta, G. F., Fletcher, C. D. �., & Loda, M. F. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.147 · Cited by 27
Emerging phytochemicals for prevention of melanoma invasion
Jones, V., & Katiyar, S. K. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.056 · Cited by 28
“Interestingly, the BRAF mutation is also frequently found in normal nevi [18], which gives further credence to the concept that multiple mutations must occur if the melanocyte is to progress down the continuum from a normal cell to melanoma.”
BackgroundChromatin barcodes as biomarkers for melanoma
Bastonini, E., Jeznach, M., Field, M., Juszczyk, K., Corfield, E., Dezfouli, M., Ahmat, N., Smith, A., Womersley, H. J., Jordan, P. W., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12258 · Cited by 27
“, 2002) and up to 83% of benign nevi (Pollock et al., 2003).”
BackgroundKaji, T., Yamasaki, O., Takata, M., Otsuka, M., Hamada, T., Morizane, S., Asagoe, K., Yanai, H., Hirai, Y., Umemura, H., et al. (2016) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2016.10.006 · Cited by 27
“Since BRAF and NRAS mutations are found both in melanoma and melanocytic nevus, it is postulated that these mutations are a founder event in melanomagenesis [28].”
Melanocytic Nevi and the Genetic and Epigenetic Control of Oncogene-Induced Senescence
Huang, J. M., Chikeka, I., & Hornyak, T. J. (2016) · Dermatologic Clinics · doi:10.1016/j.det.2016.08.001 · Cited by 38
“Up to 80% of benign nevi carry the BRAF mutation.(17) Both mutations are found at high frequency in cutaneous melanomas, with the BRAF mutation being detected in about 60% to 70% of malignant melanomas.”
BackgroundLow frequency of BRAF V600E immunoexpression in mandibular ameloblastomas: An institutional study
Shirsat, P. M., Bansal, S. P., Prasad, P., & Desai, R. S. (2018) · Journal of Oral and Maxillofacial Pathology · doi:10.4103/jomfp.jomfp_174_17 · Cited by 27
“[14] Benign lesions showing BRAF mutation include melanocytic nevi,[15] melanotic neuroectodermal tumor of infancy[16] and polyps of the colon[17] as well as ameloblastic fibroma and ameloblastic fibro‐odontomas.”
BackgroundBRAF Polymorphisms and Risk of Melanocytic Neoplasia
James, M. R., Roth, R. B., Shi, M. M., Kammerer, S., Nelson, M. R., Stark, M. S., Dumenil, T. D., Montgomery, G. W., Hayward, N. K., Martin, N. G., et al. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23937.x · Cited by 27
“…Queensland Familial Melanoma Project; SNP, single nucleotide polymorphism Copyright r 2005 by The Society for Investigative Dermatology, Inc. 1252 since their presence in any single tumor is mutually exclusive (Brose et al, 2002; Davies et al, 2002; Pollock et al, 2003; Satyamoorthy et al, 2003).”
BackgroundSelf-citationTargeting growth factors and angiogenesis; using small molecules in malignancy
Wanebo, H. J., Argiris, A. E., Bergsland, E. K., Agarwala, S. S., & Rugo, H. S. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-8508-2 · Cited by 30
Repression of cancer cell senescence by PKCι
Paget, J., Restall, I. J., Daneshmand, M., Mersereau, J. A., Simard, M. A., Parolin, D. A. E., Lavictoire, S. J., Amin, M. S., Islam, S., & Lorimer, I. A. J. (2011) · Oncogene · doi:10.1038/onc.2011.524 · Cited by 27
Saroufim, M., Habib, R., Gerges, R., Saab, J., Loya, A., Amr, S. S., Sheikh, S. S., Satti, M., Oberkanins, C., & Khalifeh, I. M. (2014) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2014.09.008 · Cited by 26
Targeted Therapy for Melanoma: A Primer
Davies, M. A., & Gershenwald, J. E. (2010) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2010.09.003 · Cited by 30
Oncogene‐induced senescence and melanoma: where do we stand?
Peeper, D. S. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00933.x · Cited by 31
Melanoma Metabolism: Cell Survival and Resistance to Therapy
Luís, R., Brito, C., & Pojo, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-34025-4_11 · Cited by 28
Gkiala, A., & Palioura, S. (2020) · Clinical ophthalmology · doi:10.2147/opth.s271569 · Cited by 31
A Mutational Survey of Acral Nevi
Smalley, K. S. M., Teer, J. K., Chen, Y. A., Wu, J.-Y., Yao, J., Koomen, J. M., Chen, W.-S., Rodriguez‐Waitkus, P., Karreth, F. A., & Messina, J. L. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.0793 · Cited by 26
Targeting Cellular Senescence with Senotherapeutics: Development of New Approaches for Skin Care
Thompson, E. L., Pitcher, L. E., Niedernhofer, L. J., & Robbins, P. D. (2021) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000009668 · Cited by 29
PTEN regulates IGF ‐1R‐mediated therapy resistance in melanoma
Wang, J., Sinnberg, T. W., Niessner, H., Dölker, R., Sauer, B., Kempf, W. E., Meier, F. E., Leslie, N. R., & Schittek, B. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12390 · Cited by 27
“As benign nevi harbor BRAF mutations at a similar frequency compared with melanomas (Pollock et al., 2003; Yazdi et al., 2003), other activated pathways or oncogenes complement the activation of the MAPK signaling pathway to increase malignancy.”
BackgroundSousa, J. F., Torrieri, R., Silva, R. R., Pereira, C. G., Valente, V., Torrieri, É., Peronni, K. C., Martins, W. K., Muto, N. H., Francisco, G., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013510 · Cited by 28
“The tissue panel included normal melanocytes (NM), melanoma cell lines (melanoma), including those harboring the activating BRAF V600E mutation (*), wild type BRAF (not marked), or with mutation status not determined (ND); and various cell lines and tissues of non-melanocytic origin (non-melanoma), including primary s…”
BackgroundInfluentialBRAF mutation detection and identification by cycling temperature capillary electrophoresis
Hinselwood, D. C., Abrahamsen, T. W., & Ekstrøm, P. O. (2005) · Electrophoresis · doi:10.1002/elps.200410427 · Cited by 26
Greshock, J. D., Nathanson, K. L., Medina, A., Ward, M. R., Herlyn, M., Weber, B. L., & Zaks, T. Z. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20651 · Cited by 26
“This is not surprising as BRAF mutations have also been found in benign nevi, suggesting that additional cooperating events may be necessary for full transformation (Pollock et al., 2003).”
BackgroundDifferential diagnosis of heavily pigmented melanocytic lesions: challenges and diagnostic approach
Aung, P. P., Mutyambizi, K., Danialan, R., Ivan, D. S., & Prieto, V. G. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-202887 · Cited by 26
Molecular and metabolic features of oncocytomas: Seeking the blueprints of indolent cancers
Luise, M. D., Girolimetti, G., Okere, B., Porcelli, A. M., Kurelac, I., & Gasparre, G. (2017) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2017.01.009 · Cited by 30
“in non-aggressive lesions is represented bymelanocytic nevi, frequently harboring the V600E mutation in the BRAF oncogene [74].”
Chen, C. Y., & Tang, H. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s80150 · Cited by 34
“It replaces the normal amino acid valine (V) with glutamic acid (E) at position 600.(4) Normal BRAF receives upstream signal from the growth factor receptor, receptor tyrosine kinase.”
BRAF V600E mutation and the tumour suppressor IGFBP7 in atypical genital naevi
Nguyen, L., Emley, A., Wajapeyee, N., Green, M. R., & Mahalingam, M. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09558.x · Cited by 25
Kakavand, H., Wilmott, J. S., Long, G. V., & Scolyer, R. A. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.010 · Cited by 27
Prognostic and predictive biomarkers in melanoma: an update
Foth, M., Wouters, J., de Chaumont, C., Dynoodt, P., & Gallagher, W. M. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2016.1126511 · Cited by 30
Genomic Landscape of Spitzoid Neoplasms Impacting Patient Management
Hillen, L. M., van den Oord, J., Geybels, M. S., Becker, J. C., Hausen, A. Z., & Winnepenninckx, V. J. L. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00344 · Cited by 29
“Common nevocellular nevi harbor activating hotspot BRAF mutations at codon 600 [∼80%, (1)].”
BackgroundHuRdling Senescence: HuR Breaks BRAF-Induced Senescence in Melanocytes and Supports Melanoma Growth
Liebig, J. K., Kuphal, S., & Bosserhoff, A. (2020) · Cancers · doi:10.3390/cancers12051299 · Cited by 41
“Interestingly, not only many melanomas but also approximately 80% of melanocytic nevi harbor such a mutation, however, alone not being sufficient for melanoma development [6,7].”
BackgroundIdentifying modules of cooperating cancer drivers
Klein, M., Cannataro, V. L., Townsend, J. P., Newman, S., Stern, D. F., & Zhao, H. (2021) · Molecular Systems Biology · doi:10.15252/msb.20209810 · Cited by 26
“From a biological perspective, cooccurrence of driver alterations clearly does occur [17, 18, 19, 20], and appears to be a requirement for carcinogenesis, as evidenced by the insufficiency of BRAF and RAS hotspot mutations to transform benign colon polyps and nevi into invasive carcinoma [21, 22].”
BackgroundTroussard, X., Maître, E., & Paillassa, J. (2024) · American Journal of Hematology · doi:10.1002/ajh.27240 · Cited by 30
“65 These data suggest that cooperating genetic and/or epigenetic events are required to facilitate malignant transformation.”
BackgroundSchlaak, M. S., Bajah, A., Podewski, T., Kreuzberg, N., von Bartenwerffer, W., Wardelmann, E., Merkelbach‐Bruse, S., Büttner, R., Mauch, C., & Kurschat, P. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12140 · Cited by 27
Melanoma genotypes and phenotypes get personal
Pimiento, J. M., Larkin, E. M., Smalley, K. S. M., Wiersma, G., Monks, N. R., Smalley, I., Peterson, C. A., & Nickoloff, B. J. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.84 · Cited by 26
Piana, S., Tagliavini, E., Ragazzi, M., Zanelli, M., Zalaudek, I., Ciarrocchi, A., & Valli, R. (2015) · Pathology - Research and Practice · doi:10.1016/j.prp.2015.01.003 · Cited by 25
Molecular Bases of Cutaneous and Uveal Melanomas
Gaudi, S., & Messina, J. L. (2011) · Pathology Research International · doi:10.4061/2011/159421 · Cited by 25
“Furthermore, a significant proportion of both benign and dysplastic melanocytic nevi have been shown to harbor mutation of BRAF as well, suggesting a relatively early event in melanomagenesis [3, 11, 12, 30].”
BackgroundThe RhoJ-BAD signaling network: An Achilles’ heel for BRAF mutant melanomas
Ruiz, R., Jahid, S., Harris, M. L., Marzese, D. M., Espitia, F., Vasudeva, P., Chen, C., de Feraudy, S. M., Wu, J., Gillen, D. L., et al. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1006913 · Cited by 28
“BRAF mutations are not exclusive to tumors as they are also seen in common human nevi [16] that spontaneously arrest [2], and little is understood about what pathways allow BRAF mutant cells to proliferate to form nevi.”
BackgroundMacroenvironment-gene-microenvironment interactions in ultraviolet radiation-induced melanomagenesis
Mo, X., Preston, S., & Zaidi, M. R. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.008 · Cited by 26
Cutaneous melanoma: pathogenesis and rationale for chemoprevention
Demierre, M., & Sondak, V. K. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.11.001 · Cited by 27
Molecular genetics of melanocytic neoplasia: practical applications for diagnosis
Bastian, B. C. (2004) · Pathology · doi:10.1080/00303020412331282717 · Cited by 25
“mutated in about 90% of melanocytic naevi.(13) More recent studies have also shown that Spitz naevi do not have any BRAF mutations,(14) which is consistent with our finding of HRAS mutations in Spitz naevi.”
ResultMcAfee, J. L., Scarborough, R., Jia, X. S., Azzato, E. M., Astbury, C., Ronen, S., Andea, A. A., Billings, S. D., & Ko, J. S. (2022) · Journal of Cutaneous Pathology · doi:10.1111/cup.14342 · Cited by 24
“BRAF V600E immunoreactivity rates did not differ significantly by FISH status, unsurprisingly, given prevalence in both benign nevi and melanoma.(47,48,69,75) When examined in the context of retained p16, BRAF V600E positivity was significantly associated with FISH positivity, showing utility as an additional screenin…”
BackgroundMcGrail, K., Granado‐Martínez, P., Esteve‐Puig, R., García-Ortega, S., Ding, Y., Sánchez‐Redondo, S., Fábrega, B. F., Hernández‐Losa, J., Canals, F., Manzano, À., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34907-0 · Cited by 31
Wilson, M. A., & Nathanson, K. L. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824f11bf · Cited by 24
“Of 77 benign nevi that were evaluated, 63 (82%) contained BRAF mutations, suggesting they are an early event in the progression to melanoma.(68) Although BRAF andNRASmutations Wilson and Nathanson The Cancer Journal & Volume 18, Number 2, March/April 2012”
BackgroundRen, L. M., Laird, E. R., Buckmelter, A. J., Dinkel, V., Gloor, S. L., Grina, J. A., Newhouse, B., Rasor, K., Hastings, G. A., Gradl, S., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.11.092 · Cited by 24
Coupling Sensitive Nucleic Acid Amplification with Commercial Pregnancy Test Strips
Du, Y., Pothukuchy, A., Gollihar, J., Nourani, A., Li, B., & Ellington, A. D. (2016) · Angewandte Chemie · doi:10.1002/ange.201609108 · Cited by 24
Microarray analysis of phosphatase gene expression in human melanoma
McArdle, L., Rafferty, M., Satyamoorthy, K., Mælandsmo, G. M., Dervan, P. A., Herlyn, M., & Easty, D. J. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06454.x · Cited by 24
No Evidence for BRAF as a Melanoma/Nevus Susceptibility Gene
Jackson, S., Harland, M., Turner, F., Taylor, C., Chambers, P. A., Randerson‐Moor, J. A., Swerdlow, A. J., dos‐Santos‐Silva, I., Beswick, S., Bishop, D. T., et al. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0568 · Cited by 29
“The high prevalence of oncogenic somatic mutations in melanoma tumors and nevi (39) suggests that mutation in this gene is a key event early in the process of melanocyte proliferation which may lead to melanoma.”
BackgroundAmphiregulin Regulates Melanocytic Senescence
Pommer, M., Kuphal, S., & Bosserhoff, A. (2021) · Cells · doi:10.3390/cells10020326 · Cited by 33
“Mutation of BRAF (like BRAFV600E) in melanocytic cells leads first to cell proliferation, followed by growth arrest, induction of tumor suppressors including p16INK4A and p21CIP1 (p21SDI1, p21WAF1, gene CDKN1), and SA β-gal expression, as senescence markers in nevi [10,11].”
BackgroundSomatic activating BRAF variants cause isolated lymphatic malformations
Zenner, K., Jensen, D. M., Dmyterko, V., Shivaram, G. M., Myers, C. T., Paschal, C. R., Rudzinski, E. R., Pham, M.-H. M., Cheng, V. C., Manning, S. C., et al. (2022) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2022.100101 · Cited by 23
“Val600Glu variants are detected in >80% of benign melanocytic nevi, indicating that the single mutation is insufficient to produce melanoma.(38) All three individuals with BRAF p.”
BackgroundInactivation of the Hippo tumor suppressor pathway promotes melanoma
Vittoria, M. A., Kingston, N. M., Kotýnková, K., Xia, E., Hong, R., Huang, L., McDonald, S., Tilston-Lünel, A., Darp, R., Campbell, J. D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31399-w · Cited by 31
“This is corroborated by clinical evidence as melanocytes within benign human nevi also frequently contain BRAFV600E mutations (11, 12) and these melanocytic nevi rarely transform into melanoma (annual rate < 0.”
BackgroundChen, J.-Y., Hug, C. B., Reyes, J. S., Tian, C., Gerosa, L., Fröhlich, F., Ponsioen, B., Snippert, H. J. G., Spencer, S. L., Jambhekar, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112252 · Cited by 26
Whole-Genome Doubling as a source of cancer: how, when, where, and why?
Sanz‐Gómez, N., González-Álvarez, M., Rivas, J. D. L., & de Cárcer, G. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1209136 · Cited by 24
“Interestingly, these oncogenic alterations together with the senescent response are also present in nevi (Pollock et al., 2002; Michaloglou et al., 2005).”
BackgroundThe oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites
Deichmann, M., Krahl, D., Thome, M., Wüst, K., Hassanzadeh, J., & Helmke, B. M. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.1.139 · Cited by 23
Kashani–Sabet, M. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12493 · Cited by 28
Cochran, A. J., Binder, S. W., & Morton, D. L. (2010) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2010.01509.x · Cited by 23
Innate extracellular vesicles from melanoma patients suppress β-catenin in tumor cells by miRNA-34a
Lee, J., Dindorf, J., Eberhardt, M., Lai, X., Ostalecki, C., Koliha, N., Gross, S., Blume, K., Bruns, H., Wild, S., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201800205 · Cited by 25
Role of melanoma inhibitory activity in melanocyte senescence
Feuerer, L., Lamm, S., Henz, I., Kappelmann‐Fenzl, M., Haferkamp, S., Meierjohann, S., Hellerbrand, C., Kuphal, S., & Bosserhoff, A. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12801 · Cited by 39
Symvoulakis, E. K., Zaravinos, A., Panutsopulos, D., Zoras, O., Papalambros, E. L., Sigala, F., & Spandidos, D. A. (2007) · The International Journal of Biological Markers · doi:10.1177/172460080702200102 · Cited by 23
“This mutation converts a valine residue to a glutamic acid (V600E) at amino acid position 600, previously reported as V599E (12, 14, 15).”
BackgroundKim, L., Kim, Y. S., Lee, J. S., Choi, S. J., Park, I. S., Han, J. Y., Kim, J. M., & Chu, Y. C. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.11.120 · Cited by 22
“For example, most acquired melanocytic nevi and a subset of colonic serrated polyps/adenomas have this mutation (9,10).”
BackgroundRaghavan, S. S., Saleem, A., Wang, J. Y., Rieger, K. E., Brown, R. A., & Novoa, R. A. (2020) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001513 · Cited by 22
PTEN: A novel target for vitamin D in melanoma
Shariev, A., Painter, N., Reeve, V. E., Haass, N. K., Rybchyn, M. S., Ince, F. A., Mason, R. S., & Dixon, K. M. (2022) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2022.106059 · Cited by 25
Biology of Melanocytes and Primary Melanoma
Zaidi, M. R., Fisher, D. E., & Rizos, H. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_42 · Cited by 28
Park, S., & Yun, S. J. (2022) · Dermatopathology · doi:10.3390/dermatopathology9030035 · Cited by 22
Hay, R. W., Macrae, E. R., Barber, D., Khalil, M., & Demetrick, D. J. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-1361-bmimla · Cited by 24
Clinical and Epidemiologic Profile of Melanoma Patients According To Sun Exposure Of The Tumor Site
Nagore, E., Estrada, R. B., Requena, C., Serra-Guillén, C., Martorell, A., Hueso, L., Llombart, B., Sanmartín, O., & Guillén, C. (2009) · Actas Dermo-Sifiliográficas · doi:10.1016/s1578-2190(09)70046-0 · Cited by 22
Braf V600E mutation in melanoma: translational current scenario
Guadarrama-Orozco, J. A., Ortega-Gómez, A., Ruíz‐García, E., la Vega, H. A., Meneses-García, A. A., & López‐Camarillo, C. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1469-6 · Cited by 28
Senescence-Like Phenotypes in Human Nevi
Joselow, A., Lynn, D., Terzian, T., & Box, N. F. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6670-7_17 · Cited by 29
“BRAFV600E is the most common oncogenic mutation found in human melanomas (8, 9).”
BackgroundMolecular Melanoma Diagnosis Update
Lang, U. E., Yeh, I., & McCalmont, T. H. (2017) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2017.06.002 · Cited by 22
Metadata
- Authors
- Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Kallioniemi, O., Hayward, N. K., Trent, J. M., & Meltzer, P. S.
- Affiliations
- National Institutes of Health (US)
- QIMR Berghofer Medical Research Institute (AU)
- The University of Western Australia (AU)
- Corresponding author
- Meltzer, Paul S.
- ORCID
- Venue
- Nature Genetics
- Published
- 2002-11-25
- Volume
- 33
- Issue
- 1
- Pages
- 19-20
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1565041471
- Cited by
- 1,730
- References
- 4
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 40 · 2023: 49 · 2022: 46 · 2021: 73 · 2020: 58 · 2019: 73 · 2018: 67 · 2017: 87 · 2016: 79 · 2015: 87 · 2014: 84 · 2013: 104 · 2012: 92
- FWCI
- 25.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- BRAF mutation, melanocytic nevi, melanoma, melanoma metastasis, RAS/MAPK pathway, carcinogenesis
- MeSH terms
- Cell Transformation, Neoplastic, DNA Mutational Analysis, Gene Frequency, Humans, Melanoma, Nevus, Signal Transduction, Polymerase Chain Reaction, Genetic Predisposition to Disease, Mutation, Missense, Oncogene Proteins v-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.